<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5608">
  <stage>Registered</stage>
  <submitdate>6/01/2012</submitdate>
  <approvaldate>6/01/2012</approvaldate>
  <nctid>NCT01507168</nctid>
  <trial_identification>
    <studytitle>A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma</studytitle>
    <scientifictitle>A Randomised, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients With Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-003574-84</secondaryid>
    <secondaryid>NP27884</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoma, Hepatocellular</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - RO5137382

Placebo Comparator: Placebo - 

Experimental: RO5137382 (GC33) - 


Treatment: drugs: Placebo
iv Days 1 and 8, and every 2 weeks thereafter

Treatment: drugs: RO5137382
1600 mg iv Day 1 and 8, and every 2 weeks thereafter

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (tumor assessments according to RECIST criteria)</outcome>
      <timepoint>approximately 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>approximately 32 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progression (TTP): Time from randomization to first documented disease progression</outcome>
      <timepoint>approximately 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease control rate (DCR): Complete response, partial response or stable disease lasting at least 6 weeks</outcome>
      <timepoint>approximately 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>approximately 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Serum concentrations (Cmax,Cmin)</outcome>
      <timepoint>Multiple sampling pre- and post-dose Days 1 and 8 Cycle 1, Day 1 Cycle 6, pre-dose Day 1 Cycles 2-11</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>GPC-3 expression in tumor tissue (biopsy) by immunohistochemistry (IHC) assay</outcome>
      <timepoint>at screening</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult patients, &gt;/= 18 years of age

          -  Histologically confirmed hepatocellular carcinoma (without fibro-lamellar subtype)

          -  Prior treatment with at least 1 systemic agent, with documented progressive disease
             after systemic agent(s), or documented adverse event(s) associated with prior systemic
             agent(s) that resulted in discontinuance of that (those) agent(s)

          -  Not a candidate for curative treatments (e.g. resection, transplantation)

          -  Child-Pugh A (score of 5-6)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Adequate hematologic, hepatic and renal function

          -  Ability to provide, for central review, a tumor tissue sample to determine the level
             of GPC-3 expression by IHC

          -  Measurable disease by RECIST criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Child Pugh B or C

          -  Known hepatocellular carcinoma with fibro-lamellar histology

          -  Known brain or leptomeningeal metastases

          -  Active infectious diseases requiring treatment except for hepatitis B and C

          -  History of organ allograft including liver transplant

          -  Anticipated or ongoing administration of anticancer therapies other than those
             administered in this study

          -  Anticancer treatment within 2 weeks prior to entering the study

          -  Patients who have not fully recovered from toxicities associated with previous HCC
             loco-regional or systemic therapies

          -  Patients receiving interferon therapy

          -  Pregnant or lactating women

          -  Known HIV positivity or AIDS-related illness

          -  History of significant hypersensitivity to similar agents (monoclonal antibody,
             protein-included drugs, Chinese hamster ovary products)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>186</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Angers</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-les-nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt Am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>TÃ¼bingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Pokfulam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Campania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ishikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cantabria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Zaragoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bebington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, placebo-controlled, multicenter study will evaluate the efficacy and safety
      of RO5137382 (GC33) in previously treated patients with unresectable advanced or metastatic
      hepatocellular carcinoma. Patients will be stratified according to the level of GPC-3
      expression in tumors and randomized to receive either RO5137382 (1600 mg intravenously) or
      placebo on Days 1 and 8 of Cycle 1 and every 2 weeks thereafter. Anticipated time on study
      treatment is until disease progression or unacceptable toxicity occurs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01507168</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>